MedPath

Spiriva

These highlights do not include all the information needed to use SPIRIVA HANDIHALER safely and effectively. See full prescribing information for SPIRIVA HANDIHALER. SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder), for oral inhalation use Initial U.S. Approval: 2004

Approved
Approval ID

ba462261-734a-4e9f-a5c0-5c676bc56a2e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 6, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TIOTROPIUM BROMIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-4248
Application NumberNDA021395
Product Classification
M
Marketing Category
C73594
G
Generic Name
TIOTROPIUM BROMIDE
Product Specifications
Route of AdministrationORAL, RESPIRATORY (INHALATION)
Effective DateNovember 30, 2021
FDA Product Classification

INGREDIENTS (1)

TIOTROPIUM BROMIDE MONOHYDRATEActive
Quantity: 18 ug in 1 1
Code: L64SXO195N
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Spiriva - FDA Drug Approval Details